21 CFR 210cGMP in Manufacturing, Processing, Packing, or Holding of Drugs — General

21 CFR Part 210 is the introductory part of the FDA's current Good Manufacturing Practice (cGMP) regulations for drugs. It is short — three sections — but it carries the legal weight that makes the rest of Subchapter C (Parts 211, 212, 225, 226) enforceable against any manufacturer of a finished pharmaceutical, an active ingredient, a medicated feed or a Type-A medicated article.

The three sections are 210.1 (status of cGMP regulations), 210.2 (applicability), and 210.3 (definitions). Together they answer three questions: what does failing to follow cGMP mean legally, which products are covered, and what do the words used in Parts 211 and 212 actually mean. Every Part-211 inspection cites Part 210 by reference, even if the citation is implicit.

Section 210.1 states that the regulations in Parts 210, 211, 225 and 226 contain the minimum current Good Manufacturing Practice for the methods, facilities and controls used for the manufacture, processing, packing or holding of a drug product. The legal consequence sits in section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act: failure to comply renders the drug adulterated. Adulterated drugs are illegal to introduce into interstate commerce.

The word 'minimum' is important. cGMP is the floor, not the ceiling. A site can be doing more than cGMP requires (and should, for risk reasons) but cannot be doing less and remain on the market. The word 'current' is equally important: cGMP evolves with industry practice, and FDA can hold you to expectations that have become standard even if the regulation text has not changed.

Section 210.2 establishes that Parts 210 and 211 apply both to finished pharmaceuticals and, to the extent reasonable, to drug components used in their manufacture. It also handles the overlap with other rules: when a product is also subject to Part 600 (biologics) or Part 1271 (HCT/Ps), the requirements of all applicable parts apply together. The most restrictive wins.

The 2008 amendment extended cGMP applicability explicitly to active pharmaceutical ingredients in §210.2(b), aligning US practice with ICH Q7. Before 2008, API cGMP was enforced informally; after 2008 it is on the same footing as finished-product cGMP.

Section 210.3 defines roughly thirty terms that appear throughout Part 211. Mis-reading any of them creates compliance gaps that auditors find quickly. The most consequential definitions are:

Part 210 is the apex of the US drug-cGMP pyramid. Beneath it sit Part 211 (finished pharmaceuticals — the rule everyone calls 'GMP'), Part 212 (PET drugs), Part 225 (medicated feeds) and Part 226 (Type-A medicated articles). For biologics, Part 600 layers on top. For combination products, the 21 CFR Part 4 framework lets a manufacturer comply with either the device QSR/QMSR or drug Part 211, with specific elements from the other system added. For excipients there is no FDA cGMP rule directly; IPEC-PQG GMP and USP excipient monographs fill the gap.

Internationally, Part 210/211 maps to EU GMP Part I and to ICH Q7 (for API). The PIC/S GMP guide is a near-verbatim adoption of EU GMP. The bigger picture: any drug entering the US market is governed by Part 210 regardless of where it was made; foreign manufacturers receive Form 483s from FDA inspectors abroad on the same basis as domestic sites.

1. 'cGMP only applies to commercial product.' Wrong — Part 210 applies to any drug product, including Phase 2/3 clinical material. Phase 1 has FDA's 2008 separate guidance but most sponsors apply Part 211 to clinical material anyway because the infrastructure is shared.
2. 'Components are only the actives.' Wrong — §210.3 defines component as anything intended for use in manufacture, active or inactive, present in the final product or not. Solvents removed during processing are still components.
3. 'A batch is whatever the planner says it is.' Wrong — a batch is defined by the manufacturing order and the requirement of uniformity. Splitting a batch mid-process without justification is a §211.110 violation, not just a paperwork problem.
4. 'Theoretical yield is whatever the MMR says.' The MMR contains it, but §210.3 defines it in terms of components actually used — the recalculation discipline at every phase is what §211.103 requires.
5. 'cGMP and Part 11 are separate.' They are not. Part 11 governs the electronic form of any record Part 211 requires. The record obligation comes from Part 211; the electronic-controls obligation comes from Part 11. You need both.

V5's pharmaceutical profile treats the Part 210 definitions as first-class data primitives. A batch in V5 is the work-order; a lot is the inventory unit produced from a batch (often, but not always, one-to-one). Component records carry the full §210.3 metadata: identity, lot, supplier, expiry, retest, and potency factor. Theoretical and actual yield are calculated by the system at every stage from kiosk weigh-out data, never re-keyed — so the percentage-of-theoretical-yield ratio that §211.103 requires is the same number the BMR shows and the same number the production review signs off.